SARC037 Progress Announced at ASCO 2024

Patrick Grohar MD PhD, presented the SARC037 findings at ASCO 2024. SARC037 is a multicenter, phase I/II study evaluating the safety of Trabectedin administered as a 1-Hour Infusion in Ewing Sarcoma patients in combination with low dose Irinotecan and 3′-Deoxy-3′-18F Fluorothymidine (18F-FLT) Imaging. The premise of the study is that this schedule will inhibit the driver oncogene of the tumor, the ETWS::FLI1 transcription factor. The results indicate evidence of reversal of the EWS::FLI1 target.